Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

•AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter